Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-07-31
DOI
10.3389/fimmu.2018.01786
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy
- (2018) Angela Rita Elia et al. CLINICAL CANCER RESEARCH
- BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody
- (2018) Martina Sanlorenzo et al. CLINICAL CANCER RESEARCH
- Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
- (2018) Rajani Ravi et al. Nature Communications
- Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
- (2018) Charlotte E. Ariyan et al. Cancer Immunology Research
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies
- (2017) Zoila Lopez-Bujanda et al. JOURNAL OF LEUKOCYTE BIOLOGY
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Effective combinatorial immunotherapy for castration-resistant prostate cancer
- (2017) Xin Lu et al. NATURE
- Chromatin states define tumour-specific T cell dysfunction and reprogramming
- (2017) Mary Philip et al. NATURE
- Identification of essential genes for cancer immunotherapy
- (2017) Shashank J. Patel et al. NATURE
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Exhaustion-associated regulatory regions in CD8+tumor-infiltrating T cells
- (2017) Giuliana P. Mognol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer
- (2017) Sabina Davidsson et al. PROSTATE
- IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours
- (2017) Hyungseok Seo et al. Nature Communications
- Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration
- (2017) Monica Gordon-Alonso et al. Nature Communications
- Hepatocellular Carcinomas Originate Predominantly from Hepatocytes and Benign Lesions from Hepatic Progenitor Cells
- (2017) Krishna S. Tummala et al. Cell Reports
- Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature
- (2017) Sara M. Melief et al. Cancer Immunology Research
- IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients
- (2017) Rossana Tallerico et al. OncoImmunology
- Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status
- (2017) Junlong Wu et al. Scientific Reports
- T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors
- (2016) Teresa Manzo et al. CANCER RESEARCH
- NFAT1 Directly Regulates IL8 and MMP3 to Promote Melanoma Tumor Growth and Metastasis
- (2016) E. Shoshan et al. CANCER RESEARCH
- Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
- (2016) Curtis A. Clark et al. CANCER RESEARCH
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells
- (2016) Meromit Singer et al. CELL
- Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
- (2016) Andrea Schietinger et al. IMMUNITY
- Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
- (2016) Frank A. Schildberg et al. IMMUNITY
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- The epigenetic landscape of T cell exhaustion
- (2016) D. R. Sen et al. SCIENCE
- Cell surface galectin-3 defines a subset of chemoresistant gastrointestinal tumor-initiating cancer cells with heightened stem cell characteristics
- (2016) Matthias Ilmer et al. Cell Death & Disease
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
- (2015) T. W. Chen et al. ANNALS OF ONCOLOGY
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression
- (2015) Alberto Sada Japp et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation
- (2015) E. Jachetti et al. CANCER RESEARCH
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
- (2015) Chiao-Wen Kang et al. Scientific Reports
- Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
- (2015) T. Kouo et al. Cancer Immunology Research
- PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer
- (2015) J. J. Severson et al. Cancer Immunology Research
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- Chronic viral infection promotes sustained Th1-derived immunoregulatory IL-10 via BLIMP-1
- (2014) Ian A. Parish et al. JOURNAL OF CLINICAL INVESTIGATION
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- Prognostic Value of T Cell Immunoglobulin Mucin-3 in Prostate Cancer
- (2013) Yong-Rui Piao et al. Asian Pacific Journal of Cancer Prevention
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
- (2013) Stefania Laurent et al. Journal of Translational Medicine
- Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells
- (2013) Fabrizio Marcucci et al. mAbs
- Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells
- (2013) Gencheng Han et al. Frontiers in Immunology
- Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes
- (2013) Matteo Bellone et al. Frontiers in Oncology
- Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9
- (2012) M. K. Gleason et al. BLOOD
- Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy
- (2012) Nicolò Rigamonti et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Galectin-3 Contributes to Melanoma Growth and Metastasis via Regulation of NFAT1 and Autotaxin
- (2012) R. R. Braeuer et al. CANCER RESEARCH
- Constitutive Clathrin-mediated Endocytosis of CTLA-4 Persists during T Cell Activation
- (2012) Omar S. Qureshi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting TNF- to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy
- (2012) A. Calcinotto et al. JOURNAL OF IMMUNOLOGY
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence
- (2012) Judith S. Knapp et al. WORLD JOURNAL OF UROLOGY
- Won’t you come on in? How to favor lymphocyte infiltration in tumors
- (2012) Matteo Bellone et al. OncoImmunology
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
- (2011) Lukas Baitsch et al. JOURNAL OF CLINICAL INVESTIGATION
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
- (2011) P. Hemon et al. JOURNAL OF IMMUNOLOGY
- Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes
- (2011) Ying Zhang et al. JOURNAL OF LEUKOCYTE BIOLOGY
- A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
- (2010) N. Demotte et al. CANCER RESEARCH
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells
- (2010) V. Dardalhon et al. JOURNAL OF IMMUNOLOGY
- Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
- (2009) M. Nakayama et al. BLOOD
- Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing
- (2008) K. S. Sfanos et al. CLINICAL CANCER RESEARCH
- Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer
- (2008) Matteo Bellone et al. TRENDS IN IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started